Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neuroscience ; 289: 99-105, 2015 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-25592427

RESUMO

Tastes and odors influence the perception of a meal. Especially food aromas can act as potent signals to modulate our eating behavior with strong dependency on the reward produced by food. In this investigation we aimed to study the electrophysiological response to food- and non-food-related odors in healthy volunteers. Analyses revealed specific scalp potential maps for the two conditions; in particular the source of the map in the "food" condition seemed to be associated with the processing of rewards; the specific map in the "non-food" condition reflects odor characteristics excluding the reward.


Assuntos
Encéfalo/fisiologia , Potenciais Evocados/fisiologia , Alimentos , Odorantes , Percepção Olfatória/fisiologia , Adolescente , Adulto , Mapeamento Encefálico , Convallaria , Eletroencefalografia , Fragaria , Humanos , Estimulação Física , Psicofísica , Processamento de Sinais Assistido por Computador , Adulto Jovem
2.
J Clin Oncol ; 26(15): 2482-8, 2008 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-18427152

RESUMO

PURPOSE: Screening mammography guidelines for patients age 80 years and older are variable. We determined the effect of mammography use on stage at breast cancer diagnosis and survival among women of this age range. PATIENTS AND METHODS: We used the linked Surveillance, Epidemiology, and End Results-Medicare database to evaluate 12,358 women >or= 80 years of age diagnosed with breast cancer between 1996 and 2002. Patients were grouped according to number of mammograms during the 60 months before diagnosis: nonusers (0 mammograms), irregular users (one to two mammograms), and regular users (three or more mammograms). Effects of mammography on disease stage (I to IIa v IIb to IV) and survival were determined by logistic regression and Cox proportional hazards analyses. RESULTS: Percentages of women with nonuse, irregular use, and regular use of mammography during the 5 years preceding diagnosis were 49%, 29%, and 22%, respectively. On multivariate analysis, patients were 0.37 times less likely to present with late-stage cancer for each mammogram obtained (odds ratio, 0.63; 95% CI, 0.63 to 0.67). Breast cancer-specific 5-year survival among nonusers was 82%, that among irregular users was 88%, and that among regular users was 94%. However, survival from causes other than breast cancer was also associated with mammography use, suggesting a bias for healthier patients to undergo mammography. CONCLUSION: Regular mammography among women >or= 80 years of age was associated with earlier disease stage, although improved survival remains difficult to demonstrate. Health care providers should consider discussing the potential benefits of screening mammography with their older patients, particularly for those without significant comorbidity.


Assuntos
Neoplasias da Mama/diagnóstico , Mamografia/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama/mortalidade , Feminino , Humanos , Medicare , Estadiamento de Neoplasias , Programa de SEER , Taxa de Sobrevida , Estados Unidos/epidemiologia
3.
Intern Med ; 38(8): 636-42, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10440499

RESUMO

OBJECT: Mizoribine (MZR), imidazole nucleotide, inhibits purine synthesis and helper T cell functions. It is used as an immunosuppressant in chronic rheumatic arthritis in Japan. Twenty-four patients with relapsing-remitting and chronic progressive multiple sclerosis (MS) were studied for the long-term effects of MZR over 8 years. METHODS: Average daily MZR doses of 200 mg along with prednisolone (PSL) were administered in the patients studied. Ten of 24 patients were treated for more than 5 years. RESULTS: The mean relapse rate per year at entry (1.50 +/- 0.24, mean +/- SE, n = 22) decreased [0.46 +/- 0.24 (n = 19)] after two years. In 70% of the patients, the disability did not worsen. Eleven of 18 patients showed a mild decrease of the total lesion size in magnetic resonance imaging (MRI). CONCLUSION: MZR was well tolerated and could be used for long-term in MS as an adjunctive immunosuppressant to PSL, and the PSL doses could be decreased. A further randomized controlled trial with PSL is necessary.


Assuntos
Imunossupressores/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Ribonucleosídeos/uso terapêutico , Adolescente , Adulto , Algoritmos , Anti-Inflamatórios/efeitos adversos , Anti-Inflamatórios/uso terapêutico , Criança , Quimioterapia Combinada , Feminino , Humanos , Imunossupressores/efeitos adversos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Prednisolona/efeitos adversos , Prednisolona/uso terapêutico , Recidiva , Ribonucleosídeos/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...